Participations à des congrès et colloques internationaux (60)
2.
De Fisenne, M.-A., Houben, S., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2022). Intravenous injection of PHF-Tau proteins from Alzheimer Brain exacerbates neuroinflammation, Amyloid beta, and tau pathologies in 5XFAD transgenic mice.. Vol. 145 (p. 411) Abstract session presented at International conference on Alzheimer and Parkinson's diseases(15-20 Mars 2022: Barcelona).3.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2022). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models.. Vol. 130 (p. 176) Abstract session presented at International conference on Alzheimer and Parkinson’s diseases(15-22 mars 2022: Barcelona).4.
De Fisenne, M.-A., Yilmaz, Z., De Decker, R., Suain, V., Mansour, S., Buée, L., Ando, K., Brion, J. P., & Leroy, K. (2021). Alzheimer PHF-tau do not spread tau pathology to the brain via the retinotectal pathway after intraocular injection in mouse models. (p. 54) Abstract session presented at Oral presentation to the Third Eurotau meeting(October 25-26,: Lille, France).5.
Doeraene, E., Erneux, C., Yilmaz, Z., Mansour, S., Suain, V., Turbant, S., Duyckaerts, C., Brain Bank NeuroCEB Neuropathology Network,, Schurmans, S., Brion, J. P., Leroy, K., & Ando, K. (2021). Protein level and solubility of the PI 5-phosphatase SHIP2 is altered in correlation with amyloid pathology in Alzheimer’s brains. (p. 102) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).6.
Ando, K., De Decker, R., Vergara Panos, C., Yilmaz, Z., Mansour, S., Suain, V., Slegers, K., De Fisenne, M.-A., Houben, S., Potier, M.-C., Duyckaerts, C., Watanabe, T., Buée, L., Leroy, K., & Brion, J. P. (2021). Picalm reduction exacerbates tau pathology in a murine tauopathy model. (p. 77, Poster 04) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).7.
Kosa, A.-C., Ando, K., Lasri, H., Yilmaz, Z., Doeraene, E., López Gutiérrez, L., De Decker, R., Mansour, S., Suain, V., & Brion, J. P. (2021). Deletion of murine APP accelerates cognitive deficits in a murine model of amyloid and tau pathologies. (p. 129) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium.).8.
Ando, K., Ndjim, M., Turbant, S., Fontaine, G., Pregoni, G., Dauphinot, L., Suain, V., Mansour, S., Authelet, M., De Decker, R., Delatour, B., Brain Bank NeuroCEB Neuropathology Network,, Duyckaerts, C., Leroy, K., Potier, M.-C., & Brion, J. P. (2021). The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer’s disease. (p. 60) Abstract session presented at Poster presentation to the Third Eurotau meeting(October 25-26, 2021: Lille, France).9.
De Fisenne, M.-A., Houben, S., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2021). Intravenous injection of PHF-tau proteins from Alzheimer brain exacerbates neuroinflammation, amyloid beta and tau pathologies in APP/PS1 transgenic mice. (p. 98) Abstract session presented at New Horizons in Alzheimer’s Disease(October 27-28, 2021: Leuven, Belgium).10.
Doeraene, E., Erneux, C., Yilmaz, Z., Mansour, S., Suain, V., Turbant, S., Duyckaerts, C., Brain Bank NeuroCEB Neuropathology Network,, Schurmans, S., Brion, J. P., Leroy, K., & Ando, K. (2021). Protein level and solubility of the PI 5-phosphatase SHIP2 is altered in correlation with Amyloid pathology in Alzheimer’s brains. (p. 75) Abstract session presented at Poster presentation to the Third Eurotau meeting(October 25-26: Lille, France).11.
De Fisenne, M.-A., Houben, S., Ando, K., Vanden Dries, V., Poncelet, L., Yilmaz, Z., Mansour, S., De Decker, R., Brion, J. P., & Leroy, K. (2021). Intravenous injection of PHF-tau proteins from Alzheimer brain exacerbates neuroinflammation, amyloid beta and tau pathologies in APP/PS1 transgenic mice. (p. 72) Abstract session presented at Poster presentation to the Third Eurotau meeting(October 25-26: Lille, France).12.
Kosa, A.-C., Ando, K., Lasri, H., Yilmaz, Z., Doeraene, E., López Gutiérrez, L., De Decker, R., De Fisenne, M.-A., Suain, V., Buée, L., Brion, J. P., & Leroy, K. (2021). Deletion of murine APP accelerates cognitive deficits in a murine model of amyloid and tau pathologies. (p. 88) Abstract session presented at Poster presentation to the Third Eurotau meeting(October 25-26: Lille, France).13.
López Gutiérrez, L., Kosa, A.-C., De Decker, R., Yilmaz, Z., Suain, V., Brion, J. P., Ando, K., & Leroy, K. (2021). Comparison of tau seeding activities between Alzheimer disease and FTLD- MAPT-G335A mutation. (p. 96) Abstract session presented at Poster presentation to the Third Eurotau meeting(October 25-26: Lille, France).